-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Down 15.7% in September
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Short Interest Down 15.7% in September
Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Rating) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 401,400 shares, a decline of 15.7% from the August 31st total of 476,400 shares. Based on an average trading volume of 377,400 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.8% of the shares of the company are sold short.
Connect Biopharma Trading Up 5.7 %
Shares of NASDAQ:CNTB traded up $0.07 during mid-day trading on Friday, reaching $1.29. 156,903 shares of the company traded hands, compared to its average volume of 76,999. The company's 50 day moving average price is $1.30 and its 200-day moving average price is $1.51. Connect Biopharma has a 52 week low of $0.56 and a 52 week high of $24.70.
Get Connect Biopharma alerts:Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. bought a new position in Connect Biopharma in the 4th quarter worth approximately $6,438,000. Citadel Advisors LLC bought a new position in Connect Biopharma in the 2nd quarter worth approximately $357,000. DAFNA Capital Management LLC bought a new position in Connect Biopharma in the 2nd quarter worth approximately $218,000. Kynam Capital Management LP bought a new position in Connect Biopharma in the 1st quarter worth approximately $688,000. Finally, UBS Group AG boosted its stake in Connect Biopharma by 5,552.1% in the 2nd quarter. UBS Group AG now owns 105,185 shares of the company's stock worth $91,000 after purchasing an additional 103,324 shares during the period. 27.19% of the stock is currently owned by institutional investors.
About Connect Biopharma
(Get Rating)Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
Featured Stories
- Get a free copy of the StockNews.com research report on Connect Biopharma (CNTB)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Thor Industries Hammers Out A Bottom
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Rating) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 401,400 shares, a decline of 15.7% from the August 31st total of 476,400 shares. Based on an average trading volume of 377,400 shares, the days-to-cover ratio is currently 1.1 days. Approximately 0.8% of the shares of the company are sold short.
康乃德生物控股有限公司(纳斯达克:CNTB-GET评级)在9月份看到空头股数的股价大幅下跌。截至9月15日,空头股数共有40.14万股,较8月31日的47.64万股减少15.7%。以377,400股的平均成交量计算,目前天数与回补比率为1.1天。该公司约0.8%的股份被卖空。
Connect Biopharma Trading Up 5.7 %
康乃德生物交易价格上涨5.7%
Shares of NASDAQ:CNTB traded up $0.07 during mid-day trading on Friday, reaching $1.29. 156,903 shares of the company traded hands, compared to its average volume of 76,999. The company's 50 day moving average price is $1.30 and its 200-day moving average price is $1.51. Connect Biopharma has a 52 week low of $0.56 and a 52 week high of $24.70.
纳斯达克:CNTB股价周五午盘上涨0.07美元,至1.29美元。该公司有156,903股易手,而其平均成交量为76,999股。该公司的50日移动均线价格为1.30美元,200日移动均线价格为1.51美元。康乃德生物的52周低点为0.56美元,52周高点为24.70美元。
Institutional Inflows and Outflows
机构资金流入和流出
A number of hedge funds have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. bought a new position in Connect Biopharma in the 4th quarter worth approximately $6,438,000. Citadel Advisors LLC bought a new position in Connect Biopharma in the 2nd quarter worth approximately $357,000. DAFNA Capital Management LLC bought a new position in Connect Biopharma in the 2nd quarter worth approximately $218,000. Kynam Capital Management LP bought a new position in Connect Biopharma in the 1st quarter worth approximately $688,000. Finally, UBS Group AG boosted its stake in Connect Biopharma by 5,552.1% in the 2nd quarter. UBS Group AG now owns 105,185 shares of the company's stock worth $91,000 after purchasing an additional 103,324 shares during the period. 27.19% of the stock is currently owned by institutional investors.
一些对冲基金最近改变了他们在该股的头寸。Adage Capital Partners GP L.L.C.在第四季度购买了康乃德生物的一个新头寸,价值约643.8万美元。Citadel Advisors LLC在第二季度购买了康乃德生物的一个新头寸,价值约357,000美元。达夫纳资本管理有限公司在第二季度购买了一个新的康乃德生物头寸,价值约218,000美元。凯纳姆资本管理有限公司在第一季度购买了一个新的康乃德生物头寸,价值约68.8万美元。最后,瑞银集团在第二季度增持了5,552.1%的康乃德生物股份。瑞银集团(UBS Group AG)在此期间又购买了103,324股,目前持有105,185股该公司股票,价值91,000美元。该公司27.19%的股票目前由机构投资者持有。
About Connect Biopharma
关于康乃德生物
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
康乃德生物控股有限公司是一家临床阶段的生物制药公司,专注于发现和开发用于治疗严重自身免疫性疾病和炎症的免疫调节剂。该公司的主要候选产品是CBP-201,这是一种抗白细胞介素4受体α抗体,正处于IIb阶段临床试验,用于治疗炎症性过敏性疾病,如特应性皮炎、哮喘和慢性鼻窦炎伴鼻息肉。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Connect Biopharma (CNTB)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Thor Industries Hammers Out A Bottom
- 在康乃德生物上免费获取斯托克新闻网研究报告(CNTB)
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat:回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 利润下降对CarMax价值主张的挑战
- 雷神工业走出谷底
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受康乃德生物日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对康乃德生物及相关公司评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧